A prospective, multicenter study to evaluate the effectiveness and safety of prochlorperazine in patients suffering from vestibular migraine


  • M. Ilambarathi IGNET Clinic, Nanganallur, Chennai, Tamil Nadu, India
  • Aditya Yeolekar YCM Hospital, Pimpri Colony, Pune, Maharashtra, India
  • Dhrubo Roy AMRI Hospital, Barakhola, Jadhavpur, Kolkata, West Bengal, India
  • Savyasachi Saxena NEO Clinic, Indirapuram, Ghaziabad, Uttar Pradesh, India
  • Suresh Kumar Sree Krishna ENT Care Center, Chennai, Tamil Nadu, India




Vestibular migraine, Prochlorperazine, Vestibular vertigo, Clinical response


Background: Prochlorperazine is commonly used for managing vertigo and dizziness-associated vestibular disorders. This study was designed to evaluate the effectiveness and safety of prochlorperazine in Indian patients with vestibular migraine.

Methods: In this prospective, multicenter, open-label, single-arm study, VM patients received 5 mg of prochlorperazine thrice daily for 5 days. The primary endpoint measured changes in clinical response using the scale for vestibular vertigo severity level and clinical response evaluation from baseline to days 6, 15, and 30. Secondary endpoints included symptom severity improvement and changes in SVVSLCRE from baseline up to day 30. Safety and tolerability were also assessed. Statistical analysis used the Wilcoxon signed-rank test and student-paired t-test.

Results: Out of 259 enrolled patients, 254 (98.1%) completed the study with a mean (standard deviation) age of patients was 42.22 (10.7) years; 72.2% were females. Significant improvements in clinical response and symptom severity were observed at all follow-up periods. 81.5% of patients showed VM symptom improvement by day 6, with 77.2% exhibiting moderate to good changes in SVVSLCRE scores. 83.4% experienced milder vestibular symptoms after 6 days. Furthermore, a significant difference (p<0.001) in mean values was observed from baseline at different follow-up periods. 11 (4.3%) adverse events (AEs) were reported, with headache being the most common (2, 0.8%); all AEs were unrelated to the study drug, and patients reported good tolerability.

Conclusions: Prochlorperazine showed significant improvement in clinical response and symptom severity with acceptable safety and tolerability in VM patients.


Dieterich M and Brandt T. Episodic vertigo related to migraine (90 cases): Vestibular migraine? J Neurol. 1999;246:883-92.

Neuhauser H, Lempert T. Vertigo and dizziness related to migraine: A diagnostic challenge. Cephalalgia. 2004;24(2):83-91.

Calhoun AH, Ford S, Pruitt AP, Fisher KG. The point prevalence of dizziness or vertigo in migraine and factors that influence presentation. Headache. 2011;51(9):1388-92.

Smyth D, Britton Z, Murdin L, Arshad Q, Kaski D. Vestibular migraine treatment: a comprehensive practical review. Brain. 2022;145(11):3741-54.

Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders. Cephalalgia. 2018;38(1):211.

Shen Y, Qi X, Wan T. The treatment of vestibular migraine: a narrative review. Ann Indian Acad Neurol. 2020;23(5):602-7.

Nowaczewska M. Vestibular migraine - an underdiagnosed cause of vertigo. Diagnosis and treatment. Neurol Neurochir Pol. 2020;54(2):106-15.

Beh SC, Masrour S, Smith SV, Friedman DI. The spectrum of vestibular migraine: clinical features, triggers, and examination findings. Headache. 2019;59(5):727-40.

Huang TC, Wang SJ, Kheradmand A. Vestibular migraine: An update on current understanding and future directions. Cephalalgia. 2020;40(1):107-21.

Luzeiro I, Luis L, Goncalves F, Pavao Martins I. Vestibular migraine: clinical challenges and opportunities for multidisciplinary. Behav Neurol. 2016;2016:617.

Biswas A. Vertigo-what is new in it from the general physician’s perspective. Med Update. 2012;22:586-91.

Geser R, Straumann D. Referral and final diagnoses of patients assessed in an academic vertigo center. Front Neurol. 2012;3:169.

Neuhauser HK, Radtke A, von Brevern M. Migrainous vertigo: prevalence and impact on quality of life. Neurology. 2006;67(6):1028-33.

Florida SU. Prochlorperazine the forgotten antiemetic. Drugs Ther Bull. 2009;23(6):1-6.

Chokhawala K, Stevens L. Antipsychotic medications. Treasure Island (FL): Stat Pearls Publishing; 2023.

Manteuffel J. Use of antiemetics in children with acute gastroenteritis: are they safe and effective? J Emerg Trauma Shock. 2009;2(1):3-5.

Din L, Preuss CV. Prochlorperazine. StatPearls Publishing; Treasure Island (FL): Stat Pearls Publishing; 2023.

Haldipur D, Krishnamurthy N. The real-world safety and effectiveness of prochlorperazine in Indian patients with dizziness. J Assoc Physicians India. 2020;68(2):61-6.

Singh AK, Chaturvedi VN. Prochlorperazine versus cinnarizine in cases of vertigo. Indian J Otolaryngol Head Neck Surg. 1998;50:392-7.

Kameswaran M, Bharathi MB, Periera C. Effectiveness and safety of prochlorperazine in Indian patients with acute vertigo: results from a large, prospective, post-marketing observational study. Indian J Otolaryngol Head Neck Surg. 2023;75:3152-60.

Burt CW, Schappert SM. Ambulatory care visits to physician offices, hospital outpatient departments, and emergency departments: United States, 1999-2000. Vital Health Stat. 2004;157:1-70.

Ernst AA, Weiss SJ, Park S, Takakuwa KM, Diercks DB. Prochlorperazine versus promethazine for uncomplicated nausea and vomiting in the emergency department: a randomized, double-blind clinical trial. Ann Emerg Med. 2000;36(2):89-94.






Original Research Articles